Stocktoria
Amneal Pharmaceuticals, Inc. AMRX
Amneal Pharmaceuticals, Inc. (AMRX) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the grey zone. It pays a dividend yielding 3.33% (safety: no dividend). FY2025 revenue was $3.0B at a 2.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-20 | Barclays | Overweight (main) |
| 2026-04-17 | UBS | Buy (init) |
| 2026-03-02 | Truist Securities | Buy (main) |
| 2025-12-09 | Barclays | Overweight (init) |
| 2025-10-31 | Piper Sandler | Overweight (reit) |
| 2025-09-16 | JP Morgan | Overweight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.28 |
| Retained earnings / assets | -0.145 |
| EBIT / assets | 0.107 |
| Equity / liabilities | -0.019 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AMRX | Amneal Pharmaceuticals, Inc. | 7/9 | 2.06 | 76.3 | +8% |
| UTHR | UNITED THERAPEUTICS Corp | 7/9 | 16.93 | 17.4 | +10.6% |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 4/9 | 7.43 | 32.7 | +12.9% |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | 5/9 | -0.11 | 124 | +65.2% |
| SRPT | Sarepta Therapeutics, Inc. | 4/9 | -2.78 | — | +15.6% |
| PRGO | PERRIGO Co plc | 4/9 | -0.37 | — | -2.8% |
| JAZZ | Jazz Pharmaceuticals plc | 5/9 | 1.63 | — | +4.9% |
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
FAQ
Is AMRX financially healthy?
Amneal Pharmaceuticals, Inc.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does AMRX pay a dividend, and is it safe?
Yes. Amneal Pharmaceuticals, Inc. pays a dividend yielding about 3.33% with a None payout ratio, rated “no dividend” for safety.
How profitable is AMRX?
In FY2025, Amneal Pharmaceuticals, Inc. had a net margin of 2.4%.
What is AMRX's P/E ratio?
Amneal Pharmaceuticals, Inc.'s trailing price-to-earnings (P/E) ratio is about 76.3×, based on its latest annual earnings.
What is the analyst price target for AMRX?
The average Wall-Street price target for Amneal Pharmaceuticals, Inc. is $17.25, about 2.3% below the recent price, from 4 analysts.
Is AMRX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Amneal Pharmaceuticals, Inc.: a Piotroski F-score of 7/9, an Altman Z″ in the grey zone, a P/E of about 76.3×, a dividend yield of 3.33%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.